Chapin Davis Inc. Takes $200,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Chapin Davis Inc. acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 825 shares of the biopharmaceutical company’s stock, valued at approximately $200,000.

Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 2.5% in the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock worth $2,286,181,000 after buying an additional 287,064 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its position in Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 12,513 shares during the last quarter. Quattro Financial Advisors LLC boosted its holdings in Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after acquiring an additional 4,809 shares during the period. Westpac Banking Corp grew its position in shares of Alnylam Pharmaceuticals by 59.8% in the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 566 shares during the last quarter. Finally, Plato Investment Management Ltd increased its stake in shares of Alnylam Pharmaceuticals by 2,666.3% in the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after purchasing an additional 4,346 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $269.28 on Monday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $274.93. The company’s 50 day simple moving average is $232.23 and its 200-day simple moving average is $180.32. The stock has a market capitalization of $34.06 billion, a P/E ratio of -100.09 and a beta of 0.37.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same period last year, the company earned ($2.21) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 107.0% compared to the same quarter last year. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -3.99 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on ALNY shares. Wells Fargo & Company increased their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. TD Cowen raised their price objective on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. UBS Group upped their target price on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research note on Friday, June 28th. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Finally, Evercore ISI boosted their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, June 25th. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $277.14.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the transaction, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Alnylam Pharmaceuticals news, Director Dennis A. Ausiello sold 20,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now directly owns 136 shares of the company’s stock, valued at $35,632. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the sale, the chief executive officer now owns 80,534 shares in the company, valued at $18,602,548.66. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 109,848 shares of company stock valued at $24,683,444. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.